Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Cancer Investigation
|
June 27, 2015
Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma
Hideharu Bessho, Bernice Wong, Dachuan Huang, et al.
Journal of Chemical Information and Modeling
|
October 16, 2014
Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602
Anders Poulsen, Harish Nagaraj, Angeline Lee, et al.
Journal of Hepatology
|
November 15, 2008
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention
Han Kiat Ho, Sharon Pok, Sylvia Streit, et al.
The Journal of Biological Chemistry
|
August 5, 2004
Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK
Ling Zhao, Stefan Hart, JrGang Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2012
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes
Anas Younes, Jorge Romaguera, Michelle Fanale, et al.
Molecular Cancer Therapeutics
|
March 4, 2010
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer
Veronica Novotny-Diermayr, Kanda Sangthongpitag, Chang Yong Hu, et al.
Journal of Medicinal Chemistry
|
February 21, 2012
Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis
Anthony D William, Angeline C-H Lee, Anders Poulsen, et al.
Journal of Hepatology
|
September 3, 2013
Reduction of HBV replication prolongs the early immunological response to IFNα therapy
Anthony T Tan, Long Truong Hoang, Daniel Chin, et al.
Journal of Medicinal Chemistry
|
May 25, 2011
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma
Anthony D William, Angeline C-H Lee, Stéphanie Blanchard, et al.
Molecular Cancer Therapeutics
|
December 29, 2012
VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer
Stefan Hart, Veronica Novotny-Diermayr, Kee Chuan Goh, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Cancer Investigation
|
June 27, 2015
Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma
Hideharu Bessho, Bernice Wong, Dachuan Huang, et al.
Journal of Chemical Information and Modeling
|
October 16, 2014
Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602
Anders Poulsen, Harish Nagaraj, Angeline Lee, et al.
Journal of Hepatology
|
November 15, 2008
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention
Han Kiat Ho, Sharon Pok, Sylvia Streit, et al.
The Journal of Biological Chemistry
|
August 5, 2004
Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK
Ling Zhao, Stefan Hart, JrGang Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2012
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes
Anas Younes, Jorge Romaguera, Michelle Fanale, et al.
Molecular Cancer Therapeutics
|
March 4, 2010
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer
Veronica Novotny-Diermayr, Kanda Sangthongpitag, Chang Yong Hu, et al.
Journal of Medicinal Chemistry
|
February 21, 2012
Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis
Anthony D William, Angeline C-H Lee, Anders Poulsen, et al.
Journal of Hepatology
|
September 3, 2013
Reduction of HBV replication prolongs the early immunological response to IFNα therapy
Anthony T Tan, Long Truong Hoang, Daniel Chin, et al.
Journal of Medicinal Chemistry
|
May 25, 2011
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma
Anthony D William, Angeline C-H Lee, Stéphanie Blanchard, et al.
Molecular Cancer Therapeutics
|
December 29, 2012
VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer
Stefan Hart, Veronica Novotny-Diermayr, Kee Chuan Goh, et al.
Page
of 3